| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1358735 | Bioorganic & Medicinal Chemistry Letters | 2015 | 5 Pages |
Abstract
A new family of 3-aroylindolizines bearing a dimethoxytriazine unit in their position 1 was designed, synthesized and evaluated for their ability to inhibit tubulin polymerization and cellular growth in vitro. Compound 39 was the best candidate in the current study with a GI50 value of 870 nM on SNB-75 CNS cancer cells and of 920 nM on MDA-MB-231/ATCC breast cancer cells. The standard NCI Compare results indicated that indolizine 39 may target PLK1 (polo-like kinase 1).
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Liliana Lucescu, Alina Ghinet, Dalila Belei, Benoît Rigo, Joëlle Dubois, Elena Bîcu,